About
PolyPid is a late-stage biopharmaceutical company focused on improving surgical outcomes. Through locally administered, controlled, prolonged-release therapeutics, PolyPid’s proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology pairs with active pharmaceutical ingredients to enable the precise delivery of drugs at optimal release rates over durations ranging from days to months.
PolyPid’s lead product candidate, D-PLEX100, is in a phase 3 clinical trial for the prevention of abdominal colorectal surgical site infections. In addition, the company’s OncoPLEX is currently in preclinical stage testing for the treatment of solid tumors, beginning with glioblastomas.
Funding history · 13 rounds · $239.2M total
Company Intelligence Q&A
Structured intelligence from startupim data — optimized for AI retrieval and grounding.
- What is PolyPid's primary focus as a biopharmaceutical company?
- PolyPid is a late-stage biopharmaceutical company focused on improving surgical outcomes through locally administered, controlled, prolonged-release therapeutics using its proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology.
- What is the status of PolyPid's lead product candidate, D-PLEX100?
- PolyPid's lead product candidate, D-PLEX100, is in a phase 3 clinical trial for the prevention of abdominal colorectal surgical site infections.
- When did PolyPid become a public company and on which exchange?
- PolyPid became public on NASDAQ in June 2020.
- What was a significant regulatory milestone for PolyPid in March 2017?
- In March 2017, the FDA fast-tracked PolyPid.
- What was the outcome of PolyPid's Phase 3 SHIELD II trial for D-PLEX₁₀₀ in June 2025?
- In June 2025, PolyPid announced positive topline results from its Phase 3 SHIELD II trial, where D-PLEX₁₀₀ demonstrated a significant reduction in surgical site infections and met its primary and all key secondary endpoints.
- What new delivery platform did PolyPid unveil in July 2025?
- In July 2025, PolyPid unveiled a long-acting GLP-1 Receptor Agonists delivery platform, targeting the diabetes and weight loss market.
- What was a key operational development for PolyPid in September 2025 regarding manufacturing readiness?
- In September 2025, PolyPid successfully completed an Israeli Ministry of Health GMP Inspection, advancing towards commercial manufacturing readiness for D-PLEX₁₀₀.
- What was the outcome of the FDA Pre-NDA meeting for D-PLEX₁₀₀ in December 2025?
- In December 2025, PolyPid announced positive FDA Pre-NDA Meeting Minutes for D-PLEX₁₀₀, supporting its New Drug Application submission.
- What was a significant financial event for PolyPid in January 2024?
- In January 2024, PolyPid announced a private placement for $16 million in gross proceeds.
- What was the status of D-PLEX₁₀₀'s NDA submission to the FDA in March 2026?
- In March 2026, PolyPid initiated the D-PLEX₁₀₀ NDA Submission to the FDA and received a PDUFA Fee Waiver for it.